Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in <i>RAS</i> Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
|
31578276 |
2019 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.
|
30973663 |
2019 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors.
|
30621206 |
2019 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Although Daple acts as a tumor suppressor in the healthy colon, the concurrent increased abundance of Daple and epidermal growth factor receptor (EGFR) in colorectal tumors was associated with poor patient prognosis.
|
29487190 |
2018 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
This critique briefly addressed EGFR receptor characteristics, worldwide report on various cancers and EGFR based potential targeting modalities in skin, breast, ovary, brain, lungs, pancreas, gastric and colorectal tumors and molecular pathways involved in EGFR targeting.
|
29991287 |
2018 |
Colorectal Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our aim was to characterize the mutational and expression profiles of the EGFR pathway in colorectal tumors and to integrate these results according to five previously defined groups.
|
28936923 |
2017 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We screened human colorectal tumors for EGFR-positive myeloid cells and investigated their association with patient outcome.
|
28400195 |
2017 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We exploited circulating tumor DNA (ctDNA) to genotype colorectal tumors and track clonal evolution during treatment with the epidermal growth factor receptor (EGFR)-specific antibodies cetuximab or panitumumab.
|
26030179 |
2015 |
Colorectal Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Colorectal tumors evade EGFR blockade by constitutive activation of downstream signaling effectors and through mutations affecting receptor-antibody binding.
|
25623215 |
2015 |
Colorectal Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The failure of EGFR inhibitors in colorectal tumors with KRAS mutations requires the development of alternative treatment strategies for this patient subgroup.
|
24351336 |
2014 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Three different macroscopic subtypes of colorectal neoplasms display distinct carcinogenetic pathways in EGFR networking.
|
25551625 |
2014 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Activating mutations in the KRAS gene are found in more than 30% of colorectal tumors, where they are associated with a poor response to anti-epidermal growth factor receptor therapies.
|
22990113 |
2013 |
Colorectal Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Using two mouse models of colitis-associated cancer, we found that epidermal growth factor receptor inactivation accelerated the incidence and progression of colorectal tumors.
|
22772467 |
2012 |
Colorectal Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The EGFR expression levels on colorectal tumors were determined by ex vivo immunoblotting and ELISA.
|
22126621 |
2012 |
Colorectal Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
|
22270724 |
2012 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type colorectal tumors.
|
21701884 |
2011 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation.
|
20563247 |
2010 |
Colorectal Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
|
19033715 |
2009 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In addition, among colorectal tumors carrying wild-type KRAS, mutation of BRAF or PIK3CA or loss of PTEN expression may be associated with resistance to EGFR-targeted monoclonal antibody treatment, although these additional biomarkers require further validation before incorporation into clinical practice.
|
19738166 |
2009 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
K-RAS wild type colorectal tumors show an improved response rate to anti-EGFR monoclonal antibodies.
|
19712476 |
2009 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Finally, circulating TGF-alpha increased in the plasma of six patients with EGFR-negative colorectal tumors during cetuximab treatment.
|
19276250 |
2009 |
Colorectal Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe.
|
18245533 |
2008 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies.
|
18802721 |
2008 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
|
18998757 |
2008 |
Colorectal Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.
|
18154448 |
2008 |